KR880013958A - 인 함유 HMG-CoA 리덕타아제 억제제, 신규 중간체 및 방법 - Google Patents

인 함유 HMG-CoA 리덕타아제 억제제, 신규 중간체 및 방법 Download PDF

Info

Publication number
KR880013958A
KR880013958A KR1019880006020A KR880006020A KR880013958A KR 880013958 A KR880013958 A KR 880013958A KR 1019880006020 A KR1019880006020 A KR 1019880006020A KR 880006020 A KR880006020 A KR 880006020A KR 880013958 A KR880013958 A KR 880013958A
Authority
KR
South Korea
Prior art keywords
lower alkyl
methoxy
phenyl
compound
compounds
Prior art date
Application number
KR1019880006020A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 카라뉴스키 도날드
아담스 빌터 소코트
마이클 고든 에릭
Original Assignee
니콜라스 피. 말라테스티닉
아이.아르.스퀴브 앤드 산즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콜라스 피. 말라테스티닉, 아이.아르.스퀴브 앤드 산즈, 인크. filed Critical 니콜라스 피. 말라테스티닉
Publication of KR880013958A publication Critical patent/KR880013958A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/36—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
KR1019880006020A 1987-05-22 1988-05-21 인 함유 HMG-CoA 리덕타아제 억제제, 신규 중간체 및 방법 KR880013958A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5328187A 1987-05-22 1987-05-22
US053,281 1987-05-22
US10968087A 1987-10-19 1987-10-19
US109680 1987-10-19

Publications (1)

Publication Number Publication Date
KR880013958A true KR880013958A (ko) 1988-12-22

Family

ID=26731667

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880006020A KR880013958A (ko) 1987-05-22 1988-05-21 인 함유 HMG-CoA 리덕타아제 억제제, 신규 중간체 및 방법

Country Status (24)

Country Link
JP (1) JP2680347B2 (fr)
KR (1) KR880013958A (fr)
CN (1) CN88103091A (fr)
AU (1) AU610591B2 (fr)
BE (1) BE1004193A3 (fr)
CH (1) CH676984A5 (fr)
DE (1) DE3817375C2 (fr)
DK (1) DK277488A (fr)
ES (1) ES2009918A6 (fr)
FI (1) FI89493C (fr)
FR (1) FR2615508B1 (fr)
GB (1) GB2205837B (fr)
GR (1) GR1000959B (fr)
HU (1) HU205125B (fr)
IE (2) IE63760B1 (fr)
IL (1) IL86464A (fr)
IT (1) IT1217685B (fr)
NL (1) NL8801330A (fr)
NO (1) NO882218L (fr)
NZ (1) NZ224733A (fr)
PH (1) PH25350A (fr)
PL (1) PL154877B1 (fr)
PT (1) PT87539B (fr)
SE (1) SE503210C2 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU610174B2 (en) * 1987-05-22 1991-05-16 E.R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
CA2007643A1 (fr) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combinaison d'un inhibiteur de hmg coa et d'un inhibiteur de squalene synthetase et methode pour abaisser le taux de cholesterol sanguin par l'utilisation de cette combinaison
CA2042526A1 (fr) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Methode permettant de prevenir une deuxieme crise cardiaque a l'aide d'un inhibiteur de la hmg coa-reductase
US5202327A (en) * 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
GB9126144D0 (en) * 1991-12-10 1992-02-12 British Bio Technology Compounds
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
GEP20033045B (en) 1998-09-17 2003-08-25 Bristol Myers Squibb Co Method for Treating Diabetes
DE60209343T2 (de) 2001-04-11 2006-10-26 Bristol-Myers Squibb Co. Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
JP2005514337A (ja) 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー ヒトグルカゴン様ペプチド−１模倣体、並びに糖尿病および関連疾患の処置におけるその使用
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2004037181A2 (fr) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques servant de modulateurs au recepteur de cannabinoides
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP2527337A1 (fr) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibiteurs de la 11-bêta hydroxystéroïde déshydrogénase de type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
WO2007053819A2 (fr) 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Inhibiteurs à base d'amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2008057862A2 (fr) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Modulateurs de récepteur de glucocorticoïde, d'activité ap-1 et/ou nf-κb, et leur utilisation
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
WO2009023059A2 (fr) 2007-06-01 2009-02-19 The Trustees Of Princeton University Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
ES2408384T3 (es) 2007-07-27 2013-06-20 Bristol-Myers Squibb Company Nuevos activadores de glucoquinasa y procedimientos de uso de los mismos
JP5465177B2 (ja) 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2411005A1 (fr) 2009-03-27 2012-02-01 Bristol-Myers Squibb Company Procédés destinés à prévenir des événements cardiovasculaires indésirables majeurs par des inhibiteurs de la dpp-iv
WO2011014520A2 (fr) 2009-07-29 2011-02-03 Irm Llc Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
JP2013507366A (ja) 2009-10-09 2013-03-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性モジュレーターとしての化合物および組成物
PT2498759T (pt) 2009-11-13 2018-11-15 Astrazeneca Uk Ltd Formulações de comprimidos de libertação imediata
MX2012005425A (es) 2009-11-13 2012-06-14 Astrazeneca Uk Ltd Formulaciones de metformina de masa reducida.
RS57756B1 (sr) 2009-11-13 2018-12-31 Astrazeneca Ab Formulacije tableta sa dva sloja
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
JP2013523894A (ja) 2010-04-14 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼアクチベーターおよびその使用方法
PL2590634T3 (pl) 2010-07-09 2016-10-31 Skojarzony system natychmiastowego / opóźnionego uwalniania leków o krótkim okresie półtrwania, w tym remogliflozyny
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2014052619A1 (fr) 2012-09-27 2014-04-03 Irm Llc Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
CA2891773C (fr) 2012-11-20 2021-01-19 Lexicon Pharmaceuticals, Inc. Inhibiteurs du cotransporteur sodium glucose 1
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN104610262B (zh) * 2013-11-01 2017-06-06 上海医药工业研究院 联苯类化合物、中间体、制备方法、药物组合物及其应用
SG11201708323SA (en) 2015-04-30 2017-11-29 Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
JP2021530517A (ja) 2018-07-19 2021-11-11 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag ダパグリフロジンを使用してＨＦｐＥＦを処置する方法、及びダパグリフロジンを含む組成物
BR112021004839A2 (pt) 2018-09-26 2021-06-08 Lexicon Pharmaceuticals, Inc. formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828650B (en) * 1981-12-01 1983-09-28 Hunt Chem Corp Philip A Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof
FR2596393B1 (fr) * 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
AU610174B2 (en) * 1987-05-22 1991-05-16 E.R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method

Also Published As

Publication number Publication date
IT8820682A0 (it) 1988-05-20
FR2615508A1 (fr) 1988-11-25
NO882218L (no) 1988-11-23
PL272597A1 (en) 1989-03-06
JP2680347B2 (ja) 1997-11-19
GR880100331A (en) 1989-02-23
IL86464A0 (en) 1988-11-15
FR2615508B1 (fr) 1994-11-25
FI882384A (fi) 1988-11-23
IE881543L (en) 1988-11-22
GR1000959B (el) 1993-03-16
HUT49358A (en) 1989-09-28
HU205125B (en) 1992-03-30
DK277488A (da) 1988-11-23
DE3817375A1 (de) 1988-12-08
IE930324L (en) 1988-11-22
GB2205837A (en) 1988-12-21
DK277488D0 (da) 1988-05-20
AU1650888A (en) 1988-11-24
SE503210C2 (sv) 1996-04-22
FI882384A0 (fi) 1988-05-20
GB2205837B (en) 1991-11-20
SE8801903L (sv) 1988-11-23
DE3817375C2 (de) 1997-04-30
PH25350A (en) 1991-05-13
CH676984A5 (fr) 1991-03-28
IL86464A (en) 1993-06-10
GB8811929D0 (en) 1988-06-22
IE63760B1 (en) 1995-06-14
NO882218D0 (no) 1988-05-20
PT87539A (pt) 1989-05-31
FI89493C (fi) 1993-10-11
ES2009918A6 (es) 1989-10-16
FI89493B (fi) 1993-06-30
PL154877B1 (en) 1991-09-30
NZ224733A (en) 1990-12-21
PT87539B (pt) 1992-09-30
BE1004193A3 (fr) 1992-10-13
NL8801330A (nl) 1988-12-16
JPS6456689A (en) 1989-03-03
SE8801903D0 (sv) 1988-05-20
AU610591B2 (en) 1991-05-23
IT1217685B (it) 1990-03-30
CN88103091A (zh) 1988-12-21

Similar Documents

Publication Publication Date Title
KR880013958A (ko) 인 함유 HMG-CoA 리덕타아제 억제제, 신규 중간체 및 방법
DE69309753T2 (de) Phosphonooxy- und Carbonat-Derivate von Taxol
KR960000230A (ko) 간담즙성 질병 치료제
CA2565660A1 (fr) Composes aryl- ou heteroarylamides ortho-substitues
EP1884556A3 (fr) Compositions de carburant diesel contenant des espèces metalliques et des additifs détergents
ATE250618T1 (de) Neue phosphor-verbindungen
EA200401540A1 (ru) Спироиндолинпиперидиновые производные
KR880013959A (ko) 인 함유 HMG-CoA 리덕타아제 억제제, 신규 중간체 및 방법
AU3050800A (en) Functionalised polynucleotide compound, optionally marked and method for detecting a target nucleic acid
WO2001026629A3 (fr) Lipide cationique-neutre destine a l'apport d'acides nucleiques et de medicaments
EP1106621A3 (fr) Substances fluorescentes
BRPI0416670A (pt) composição de vacina misturada com uma alquilfosfatidilcolina
EP2287152A3 (fr) Procédé pour la préparation d'un dérivé de alpha-méthyle cystéine
JP2006519778A5 (fr)
KR930000527A (ko) 칼슘-길항성 물질로서의 이노시톨 포스페이트 동족체
ATE432386T1 (de) Zusammensetzung für poröse materialien
RU2002132558A (ru) Циклипостины, способ их получения и их применение
RU2217433C2 (ru) Новые цитотоксические макролиды, содержащие трис(оксазол), способ их получения, фармацевтическая композиция на их основе и способы лечения
EP1785470A3 (fr) Composition comprenant un composé sulfuré et phosphoré, et/ou son sel, et utilisations de celui-ci
WO2003075928A3 (fr) Compositions pharmaceutiques stables
KR910016659A (ko) 키랄 나프탈린디카복실레이트
FR2795077B1 (fr) Agents de complexation de cations, utiles notamment comme accelerateurs de polymerisation de monomeres insatures, leur procede de preparation et composition adhesive en contenant
KR927003583A (ko) 3-이미노-1,4-옥사티인 살균제
RU2000122441A (ru) Новые цитотоксические макролиды, содержащие трис (оксазол)
EP2356971A3 (fr) Compositions pour repousser les liquides et leurs utilisations

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application